文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

使用MOSkin探测器在前列腺SBRT增压治疗中实时测量直肠壁剂量

Real-time in vivo rectal wall dosimetry using MOSkin detectors during linac based stereotactic radiotherapy with rectal displacement.
PubMed 文献 · Radiat Oncol · 2017-02-27

BACKGROUND: MOSFET dosimetry is a method that has been used to measure in-vivo doses during brachytherapy treatments and during linac based radiotherapy treatment. Rectal displacement devices (RDDs) allow for safe dose escalation for prostate cancer treatment.…

要点

  • 双MOSkin探测器可实时测量直肠前壁剂量,用于确保治疗中直肠剂量在可接受范围内。
  • 全程实测与计划剂量平均差异为9.7%(标准差3.6%),64%的治疗弧累积读数低于计划总剂量。
  • 最终实测与最终计划剂量平均差异为最终计划剂量的3.4%(标准差10.3%)。

核心结论

  • MOSkin探测器是前列腺SBRT增压治疗中实时测量直肠前壁剂量的有效工具,可用于确保治疗中直肠剂量在可接受范围内及验证最终直肠剂量。

研究设计与样本

  • 双MOSkin探测器面对面放置以减少角度依赖性,附着于Rectafix前表面,治疗中以1 Hz频率读数。
  • 从计划系统导出各测量点的计划剂量,与实测剂量比较,计算归一化至总计划剂量的均方根误差。

主要发现

  • 全程所有测量弧的实测与计划剂量平均差异为9.7%,标准差3.6%。
  • 64%的测量弧累积MOSkin读数低于计划总剂量。
  • 所有测量弧最终实测与最终计划剂量的平均差异为最终计划剂量的3.4%,标准差10.3%。

临床怎么用

  • 在前列腺SBRT增压治疗中可使用双MOSkin探测器实时监测直肠前壁剂量,以验证直肠剂量是否在可接受范围内。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MOSFET dosimetry is a method that has been used to measure in-vivo doses during brachytherapy treatments and during linac based radiotherapy treatment. Rectal displacement devices (RDDs) allow for safe dose escalation for prostate cancer treatment. This study used dual MOSkin detectors to assess real-time in vivo rectal wall dose in patients with an RDD in place during a high dose prostate stereotactic body radiation therapy (SBRT) boost trial. METHODS: The PROMETHEUS study commenced in 2014 and provides a prostate SBRT boost dose with a RDD in place. Twelve patients received two boost fractions of 9.5-10 Gy each delivered to the prostate with a dual arc volumetric modulated arc therapy (VMAT) technique. Two MOSkins in a face-to-face arrangement (dual MOSkin) were used to decrease angular dependence. A dual MOSkin was attached to the anterior surface of the Rectafix and read out at 1 Hz during each treatment. The planned dose at each measurement point was exported from the planning system and compared with the measured dose. The root mean square error normalised to the total planned dose was calculated for each measurement point and treatment arc for the entire course of treatment. RESULTS: The average difference between the measured and planned doses over the whole course of treatment for all arcs measured was 9.7% with a standard deviation of 3.6%. The cumulative MOSkin reading was lower than the total planned dose for 64% of the arcs measured. The average difference between the final measured and final planned doses for all arcs measured was 3.4% of the final planned dose, with a standard deviation of 10.3%. CONCLUSIONS: MOSkin detectors were an effective tool for measuring dose delivered to the anterior rectal wall in real time during prostate SBRT boost treatments for the purpose of both ensuring the rectal doses remain within acceptable limits during the treatment and for the verification of final rectal doses.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Legge K, Greer PB, O'Connor DJ, et al. Real-time in vivo rectal wall dosimetry using MOSkin detectors during linac based stereotactic radiotherapy with rectal displacement. Radiat Oncol. 2017. PMID: 28241841. doi:10.1186/s13014-017-0781-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。